NasdaqGS - Delayed Quote • USD
DBV Technologies S.A. (DBVT)
At close: April 19 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.15 | -0.21 | -0.67 | -0.81 |
| Low Estimate | -0.17 | -0.23 | -0.76 | -1.14 |
| High Estimate | -0.12 | -0.18 | -0.49 | -0.42 |
| Year Ago EPS | -0.49 | -0.11 | -1.3 | -0.67 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 6.01M | 2.25M | 12.82M | 9.32M |
| Low Estimate | 410k | 1.57M | 7.23M | 6.26M |
| High Estimate | 8.85M | 3.18M | 15.62M | 13.73M |
| Year Ago Sales | -- | 1.63M | 5.08M | 12.82M |
| Sales Growth (year/est) | -- | 38.00% | 152.40% | -27.30% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.2 | -0.2 | -0.24 |
| EPS Actual | -0.49 | -0.11 | -0.13 | -0.09 |
| Difference | -0.31 | 0.09 | 0.07 | 0.15 |
| Surprise % | -172.20% | 45.00% | 35.00% | 62.50% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.21 | -0.67 | -0.81 |
| 7 Days Ago | -0.14 | -0.21 | -0.66 | -0.81 |
| 30 Days Ago | -0.15 | -0.21 | -0.67 | -0.81 |
| 60 Days Ago | -0.23 | -0.19 | -0.76 | -0.82 |
| 90 Days Ago | -0.23 | -0.18 | -0.75 | -0.81 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | DBVT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 69.40% | -- | -- | 1.60% |
| Next Qtr. | -90.90% | -- | -- | 10.50% |
| Current Year | 48.50% | -- | -- | 5.20% |
| Next Year | -20.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 21.22% | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
| Maintains | Goldman Sachs: Sell to Sell | 11/2/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 8/1/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2023 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/11/2023 |
Related Tickers
AVTE Aerovate Therapeutics, Inc.
22.05
+2.08%
ABVX ABIVAX Société Anonyme
15.31
+2.48%
GHRS GH Research PLC
11.03
-1.43%
FENC Fennec Pharmaceuticals Inc.
9.34
-2.40%
DSGN Design Therapeutics, Inc.
3.7000
-1.07%
ALGS Aligos Therapeutics, Inc.
0.7500
-5.43%
ALLK Allakos Inc.
1.0700
+0.94%
MORF Morphic Holding, Inc.
27.99
+1.74%
CDT Conduit Pharmaceuticals Inc.
3.1200
+4.35%
ACHL Achilles Therapeutics plc
0.7829
-2.14%